1. The JAK-STAT Pathway and Graft-vs-Host Disease

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Graft vs Host Disease

4. Managing GVHD

5. GVHD Pathobiology: Phase 1

6. JAKs and APC Activation

7. GVHD Pathobiology: Phase 2

8. Cytokines Drive Cellular Differentiation

9. JAKs and GVHD

10. IFNγ Receptor Knockout GVHD Mouse Model

11. T-Regulatory Cells

12. Chemokines

13. Disruption of IFNγ Signaling Through JAK1/JAK2

14. Cytokine Signaling Through the JAK-STAT Pathway

15. Phase 2 and JAKs

16. GVHD Pathobiology: Phase 3

17. Immune Regulation of Acute GVHD

18. JAKs and Chronic GVHD

19. Clinical Activity of JAK Inhibitors

20. Key Takeaways

21. Abbreviations

22. Abbreviations (cont)